Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve

This article was originally published in PharmAsia News

Executive Summary

In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services
Advertisement

Related Content

Roche Global Head of Business Development & Licensing Joe McCracken On Searching For Innovative Deals In Asia: An Interview With PharmAsia News (Part 2 of 2)
Large Chinese CROs To Benefit From Continued Outsourcing Trend, CRO Surveys Say
China's Leading CROs Go On Shopping Spree To Become One-Stop Vendors
WuXi Celebrates First $100 Million Quarter; Sinovac Reports 50% Revenue Increase; SciClone Not Worried About Zydaxin Cuts: China Earnings Round Up (Part 1)
Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma
How Much Risk Should Big Pharma Accept To Close Deals In China? (Part 2 of 2)
WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics
WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics
Charles River Abandons WuXi PharmaTech Just Days Before Crucial Shareholder Votes On Planned Merger
China's Wuxi PharmaTech Signs New Agreement On Toxicology Studies Training And Services With J&J Unit
Advertisement
UsernamePublicRestriction

Register

SC076497

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel